Journal
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
Volume 10, Issue 3, Pages 726-729Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13346-020-00743-2
Keywords
Nanomedicine; Nanotechnology; Clinical translation; Reproducibility; Cancer therapy
Ask authors/readers for more resources
This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles that broadened this discussion. Graphical abstract
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
